A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies (Q33379469)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies |
scientific article |
Statements
1 reference
A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies (English)
1 reference
Maher Albitar
1 reference
David A Rizzieri
1 reference
Eric Feldman
1 reference
John F Dipersio
1 reference
Nashat Gabrail
1 reference
Wendy Stock
1 reference
Roger Strair
1 reference
Victor M Rivera
1 reference
Camille L Bedrosian
1 reference
Francis J Giles
1 reference
1 reference
Identifiers
1 reference